Volume | 2,578,307 |
|
|||||
News | - | ||||||
Day High | 28.00 | Low High |
|||||
Day Low | 27.60 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Royalty Pharma PLC | RPRX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
27.90 | 27.60 | 28.00 | 27.98 | 27.825 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
20,778 | 2,578,307 | $ 27.80 | $ 71,684,729 | - | 25.92 - 36.19 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:18:01 | 1 | $ 27.98 | USD |
Royalty Pharma PLC Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
16.71B | 597.43M | - | 2.35B | 1.13B | 1.90 | 14.72 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Royalty Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RPRX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 27.54 | 28.40 | 27.21 | 27.84 | 2,721,007 | 0.44 | 1.60% |
1 Month | 30.42 | 30.80 | 27.21 | 28.74 | 2,596,811 | -2.44 | -8.02% |
3 Months | 28.70 | 31.655 | 27.21 | 29.60 | 2,846,997 | -0.72 | -2.51% |
6 Months | 27.50 | 31.655 | 26.07 | 28.75 | 2,573,444 | 0.48 | 1.75% |
1 Year | 36.12 | 36.19 | 25.92 | 29.65 | 2,432,084 | -8.14 | -22.54% |
3 Years | 44.00 | 47.10 | 25.92 | 36.13 | 2,117,066 | -16.02 | -36.41% |
5 Years | 45.90 | 57.50 | 25.92 | 38.27 | 2,139,115 | -17.92 | -39.04% |
Royalty Pharma Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |